A new and possibly transformative technology for rapidly diagnosing and evaluating patients based on their specific genetic profile may soon begin appearing at retail pharmacies and clinics, giving pharmacists and clinicians another tool for advancing patient health outcomes and their own practice capabilities.
Administering high-touch, expensive and complex medications to patients intravenously in their homes — or in a setting other than a hospital — is essentially a large-scale bid to “reduce costs by transferring non-self-administered drugs to the most cost-effective and clinically appropriate site of care,” said pharmacist Michael Einodshofer, senior director of specialty strategy and innovation at Walgreens Specialty Pharmacy.
A confluence of healthcare trends has expanded a lucrative, if challenging, opportunity for pharmacies able to invest in its potential.
Nowhere is the need to engage more effectively with patients more apparent than in the area of medication adherence.
It has been called “the blockbuster drug of the century,” the holy grail of health care and the next great frontier in the search for a more responsive and cost-effective healthcare system. But is it a truly achievable goal, and will it really transform the way health care is delivered in the United States?